Hoda Abdel-Aty 💙 (@hoda_aty) 's Twitter Profile
Hoda Abdel-Aty 💙

@hoda_aty

Research Fellow @ICR_London @royalmarsdenNHS | #STAMPEDE2 trial fellow @MRCCTU @UCL | ST7 Clinical Oncology Registrar | Co-host @TrialsTribsPod | Views my own

ID: 737032387821985792

calendar_today29-05-2016 21:26:29

159 Tweet

431 Followers

1,1K Following

Nick James also on @Prof-Nick-James.bsky.social (@prof_nick_james) 's Twitter Profile Photo

STAMPEDE2 now up and running. Patient reported outcomes are key to sucessful trials and current tools may not reflect patient needs and issues. As part of our QOL programme for STAMPEDE2 we have reviewed this with our patient representatives. sciencedirect.com/science/articl…

MRC Clinical Trials Unit at UCL (@mrcctu) 's Twitter Profile Photo

#ESMO24 begins this Friday and we will be presenting the latest findings from our PATCH, STAMPEDE and STAMPEDE2 #ClinicalTrials in #ProstateCancer. 📍Are you attending? We've put together a helpful guide to all our presentations and posters👇 mrcctu.ucl.ac.uk/news/news-stor…

#ESMO24 begins this Friday and we will be presenting the latest findings from our PATCH, STAMPEDE and STAMPEDE2 #ClinicalTrials in #ProstateCancer.  

📍Are you attending? We've put together a helpful guide to all our presentations and posters👇

mrcctu.ucl.ac.uk/news/news-stor…
Zach Klaassen (@zklaassen_md) 's Twitter Profile Photo

Tip: Ph 3 STAMPEDE2 Nira + AAP trial w/ HRR gene alteration #ESMO24 UroToday.com MRC Clinical Trials Unit at UCL ✏️mHSPC, 1:1 to Nira + AAP (Arm N) vs SoC (Arm A) ✏️~ 680 pts, ~80 sites in 🇬🇧 ✏️Prim EP: OS ✏️Key Sec EP: rPFS, FFS, PCSS, QoL, Tox

Tip: Ph 3 STAMPEDE2 Nira + AAP trial w/ HRR gene alteration #ESMO24 <a href="/urotoday/">UroToday.com</a> <a href="/MRCCTU/">MRC Clinical Trials Unit at UCL</a> 

✏️mHSPC, 1:1 to Nira + AAP (Arm N) vs SoC (Arm A)
✏️~ 680 pts, ~80 sites in 🇬🇧
✏️Prim EP: OS
✏️Key Sec EP: rPFS, FFS, PCSS, QoL, Tox
Zach Klaassen (@zklaassen_md) 's Twitter Profile Photo

TiP: Ph 3 STAMPEDE2 SABR Trial in Newly Dx Oligomet PCa Starting ADT #ESMO24 UroToday.com Hoda Abdel-Aty 💙 🎯2,476 pts ✏️SABR-eligible PCa (CT/MRI/BS): - 1-5 mets, bone and/or non-regional nodes - All mets SABR accessible - No visc mets ✏️1:1 to Arm A (SoC) vs Arm S (SoC + SABR)

TiP: Ph 3 STAMPEDE2 SABR Trial in Newly Dx Oligomet PCa Starting ADT #ESMO24 <a href="/urotoday/">UroToday.com</a> <a href="/Hoda_Aty/">Hoda Abdel-Aty 💙</a> 

🎯2,476 pts
✏️SABR-eligible PCa (CT/MRI/BS):
- 1-5 mets, bone and/or non-regional nodes
- All mets SABR accessible
- No visc mets
✏️1:1 to Arm A (SoC) vs Arm S (SoC + SABR)
Zach Klaassen (@zklaassen_md) 's Twitter Profile Photo

TiP - STAMPEDE2 177Lu-PSMA-617 Trial in new mHSPC UroToday.com MRC Clinical Trials Unit at UCL #ESMO24 🎯 n=1,756 ✏️1:1 to Arm A (SoC) vs Arm P (SoC + 177Lu-PSMA-617) - 177Lu-PSMA-617: 7.4 GBq on day 1 & day 8, 3x 6-weekly cycles ✏️Co-Prim EP: rPFS, OS ✏️Sec EP: FFS, PCSS, QoL, safety, tox, compliance,

TiP - STAMPEDE2 177Lu-PSMA-617 Trial in new mHSPC <a href="/urotoday/">UroToday.com</a> <a href="/MRCCTU/">MRC Clinical Trials Unit at UCL</a> #ESMO24 

🎯 n=1,756
✏️1:1 to Arm A (SoC) vs Arm P (SoC + 177Lu-PSMA-617)
- 177Lu-PSMA-617: 7.4 GBq on day 1 &amp; day 8, 3x 6-weekly cycles
✏️Co-Prim EP: rPFS, OS
✏️Sec EP: FFS, PCSS, QoL, safety, tox, compliance,
UroToday.com (@urotoday) 's Twitter Profile Photo

The #STAMPEDE2 SABR trial: A phase III, randomized, open-label trial in patients with newly diagnosed oligometastatic #ProstateCancer starting ADT. Presentation by Hoda Abdel-Aty 💙 The ICR. #ESMO24 written coverage by Zach Klaassen Georgia Cancer Center > bit.ly/4enYsJF ESMO - Eur. Oncology

The #STAMPEDE2 SABR trial: A phase III, randomized, open-label trial in patients with newly diagnosed oligometastatic #ProstateCancer starting ADT. Presentation by <a href="/Hoda_Aty/">Hoda Abdel-Aty 💙</a> <a href="/ICR_London/">The ICR</a>. #ESMO24 written coverage by <a href="/zklaassen_md/">Zach Klaassen</a> <a href="/GACancerCenter/">Georgia Cancer Center</a> &gt; bit.ly/4enYsJF <a href="/myESMO/">ESMO - Eur. Oncology</a>
National Oncology Trainees Research Collaborative (@onctrainees) 's Twitter Profile Photo

RESEARCH OPPORTUNITY 📝 Have you got a project you'd like to expand nationally? Or a study idea that you'd like to explore? Submit a project proposal by 28.10.24 using the link or drop us an email: [email protected] We'd love to hear from you! 🙌❤️uknotch.com/project-propos…

Trials & Tribulations | Oncology Trials Podcast (@trialstribspod) 's Twitter Profile Photo

Our latest episode with Mr. Ashwin Sachdeva is live! 🎙️ We dive into NHS data for trial follow-up, use of imaging in outcome assessment, balancing a surgical and academic career, and much more! Nick James also on @Prof-Nick-James.bsky.social Hoda Abdel-Aty 💙 MRC Clinical Trials Unit at UCL The ICR podcasters.spotify.com/pod/show/trial…

Matthias Guckenberger (@mat_guc) 's Twitter Profile Photo

SBRT for localized prostate cancer - the new SoC ? ! All questions to PACE-A and PACE-B studies answered by Prof. N. Van As Virtual Grand Rounds in Radiation Oncology November 6th, 17:00 - 17:45 CET Link to Zoom meeting on homepage 👇 lnkd.in/e32jAfAf

SBRT for localized prostate cancer - the new SoC ? !

All questions to PACE-A and PACE-B studies answered by Prof. N. Van As

Virtual Grand Rounds in Radiation Oncology

November 6th, 17:00 - 17:45 CET

Link to Zoom meeting on homepage 👇 
lnkd.in/e32jAfAf
Alison Tree 💙 (@alison_tree) 's Twitter Profile Photo

Are you looking for a fantastic PhD The ICR? The first three projects on the list below work directly with our Science and Innovation at Cancer Research UK Radiation Research Centre of Excellence team. All highly recommended. icr.ac.uk/studying-and-t…. Ben O'Leary @drmagnusd Anna Wilkins

National Oncology Trainees Research Collaborative (@onctrainees) 's Twitter Profile Photo

REAL-SAIF is LIVE! Retrospective Evaluation of Advanced NSCLC receiving Single-Agent ICI as 1st line therapy in the UK (REAL-SAIF) We are looking for centres to be involved in collecting data on real world outcomes in this group Get in touch via email to register your interest

REAL-SAIF is LIVE!

Retrospective Evaluation of Advanced NSCLC receiving Single-Agent ICI as 1st line therapy in the UK (REAL-SAIF)

We are looking for centres to be involved in collecting data on real world outcomes in this group

Get in touch via email to register your interest
Hoda Abdel-Aty 💙 (@hoda_aty) 's Twitter Profile Photo

Lugano, you’ve been exceptional as always—productive discussions at #APCCCDiagnostics25 with invaluable insights, and the joy of reconnecting with brilliant colleagues and friends. Hope to be back for #APCCC26

Lugano, you’ve been exceptional as always—productive discussions at #APCCCDiagnostics25 with invaluable insights, and the joy of reconnecting with brilliant colleagues and friends. Hope to be back for #APCCC26
Hoda Abdel-Aty 💙 (@hoda_aty) 's Twitter Profile Photo

🎙 New Trials and Tribulations Podcast Episode with Prof Kevin Harrington, Head of Radiotherapy& Imaging The ICR and Consultant Oncologist The Royal Marsden NHS Foundation Trust! We delve into biological agents and clinical trials 🎧 open.spotify.com/episode/27WtMQ… Nick James also on @Prof-Nick-James.bsky.social Hoda Abdel-Aty 💙

Constantinos Zamboglou (@czamboglou) 's Twitter Profile Photo

Great to see many enthusiastic colleagues at our Co-IMPACT meeting. Thanks to all for coming and bringing this huge project forward! #ESTRO2025

Great to see many enthusiastic colleagues at our Co-IMPACT meeting. Thanks to all for coming and bringing this huge project forward! #ESTRO2025
Hoda Abdel-Aty 💙 (@hoda_aty) 's Twitter Profile Photo

🔊 New podcast episode out now! spotifycreators-web.app.link/e/XO1wBvzSoTb Shankar Siva joins Nick James also on @Prof-Nick-James.bsky.social Hoda Abdel-Aty 💙 to discuss SABR in Renal Cell Cancers ⚡ Innovative trial design 📈 Meaningful endpoints 🩻 Response assessment and advanced imaging 🤝 Collaboration is key